Page last updated: 2024-12-09
2-(beta-D-glucosyl)benzothiazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 657044 |
| CHEMBL ID | 559793 |
| CHEBI ID | 45823 |
Synonyms (11)
| Synonym |
|---|
| TH1 , |
| 2-(beta-d-glucopyranosyl)-5-methyl-benzothiazole |
| 2-(beta-d-glucosyl)benzothiazole |
| (1r)-1,5-anhydro-1-(1,3-benzothiazol-2-yl)-d-glucitol |
| CHEBI:45823 , |
| CHEMBL559793 , |
| bdbm50295860 |
| (2r,3r,4s,5s,6r)-2-(benzo[d]thiazol-2-yl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol |
| (2r,3r,4s,5s,6r)-2-(1,3-benzothiazol-2-yl)-6-(hydroxymethyl)oxane-3,4,5-triol |
| 2-(beta-d-glucopyranosyl)-benzothiazole |
| Q27120633 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| C-glycosyl compound | A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond. |
| benzothiazoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glycogen phosphorylase, muscle form | Oryctolagus cuniculus (rabbit) | Ki | 127.0000 | 0.0250 | 4.8903 | 9.0000 | AID1129610; AID1280561; AID1280562; AID1321910; AID1321911; AID1333330; AID1333332; AID427132; AID760348 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1321910 | Inhibition of rabbit muscle glycogen phosphorylase b using alpha-D-glucose-1-phosphate as substrate | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21 | Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors. |
| AID760348 | Inhibition of rabbit muscle glycogen phosphorylase b | 2013 | ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7 | C-Glucopyranosyl-1,2,4-triazoles As New Potent Inhibitors of Glycogen Phosphorylase. |
| AID427132 | Inhibition of rabbit muscle glycogen phosphorylase b | 2009 | Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13 | Synthesis and structure-activity relationships of C-glycosylated oxadiazoles as inhibitors of glycogen phosphorylase. |
| AID1129610 | Inhibition of rabbit muscle glycogen phosphorylase b | 2014 | European journal of medicinal chemistry, Apr-09, Volume: 76 | New synthesis of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazoles, nanomolar inhibitors of glycogen phosphorylase. |
| AID1280562 | Inhibition of rabbit muscle glycogen phosphorylase-b | 2015 | ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12 | 4(5)-Aryl-2-C-glucopyranosyl-imidazoles as New Nanomolar Glucose Analogue Inhibitors of Glycogen Phosphorylase. |
| AID1333332 | Inhibition of rabbit muscle glycogen phosphorylase-b | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase. |
| AID1333330 | Competitive inhibition of rabbit muscle glycogen phosphorylase-b in presence of varying levels of glucose-1-phosphate and constant concentration of glycogen and AMP by double reciprocal plot method | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthetic, enzyme kinetic, and protein crystallographic studies of C-β-d-glucopyranosyl pyrroles and imidazoles reveal and explain low nanomolar inhibition of human liver glycogen phosphorylase. |
| AID1321911 | Inhibition of rabbit skeletal muscle glycogen phosphorylase b assessed as inorganic phosphate release using glucose-1-phosphate as substrate by double-reciprocal plot analysis | 2016 | Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21 | Synthesis of (benzimidazol-2-yl)aniline derivatives as glycogen phosphorylase inhibitors. |
| AID1280561 | Competitive inhibition of rabbit muscle glycogen phosphorylase-b using glucose-1-phosphate as substrate preincubated with glycogen for 15 mins followed by substrate addition measured every 1 min for 5 mins | 2015 | ACS medicinal chemistry letters, Dec-10, Volume: 6, Issue:12 | 4(5)-Aryl-2-C-glucopyranosyl-imidazoles as New Nanomolar Glucose Analogue Inhibitors of Glycogen Phosphorylase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 13.26
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.26) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||